Make text bigger  Make text smaller  Toggle background color  Bookmark/Share

HMS partners with NFL Players Association

The National Football League Players Association (NFLPA) has awarded Harvard Medical School a 0 million grant to create a transformative 10-year initiative — Harvard Integrated Program to Protect and Improve the Health of NFLPA Members. The program will marshal the intellectual, scientific, and medical expertise throughout Harvard University to discover new approaches to diagnosing, treating, and preventing injuries and illnesses in both active Read more...

Posted
February 1st, 2013

Tagged


No Comments

Mutations drive malignant melanoma

Two mutations that collectively occur in 71 percent of malignant melanoma tumors have been discovered in what scientists call the “dark matter” of the cancer genome, where cancer-related mutations haven’t been previously found. Reporting their findings in the Jan. 24 issue of Science Express, Harvard Medical School (HMS) researchers at the Dana-Farber Cancer Institute and researchers at the Broad Institute said the highly “recurrent” mu Read more...

Posted
January 26th, 2013

Tagged


No Comments

Extra chemo could be answer

Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Harvard-affiliated Dana-Farber/Children’s Hospital Cancer Center in Boston. The trial leaders today presented the results of the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia (ALL) Read more...

Posted
December 12th, 2012

Tagged


No Comments

Insulin and colon cancer linked

Colon cancer survivors whose diet is heavy in complex sugars and carbohydrate-rich foods are far more likely to have a recurrence of the disease than are patients who eat a better balance of foods, indicates a new study by researchers at Harvard-affiliated Dana-Farber Cancer Institute. The connection is especially strong in patients who are overweight or obese, the authors write. More than 1,000 patients with advanced (stage III) colon cancer par Read more...

Posted
November 9th, 2012

Tagged


No Comments

Aspirin’s impact on colorectal cancer

Aspirin therapy can extend the life of colorectal cancer patients whose tumors carry a mutation in a key gene, but it has no effect on patients who lack the mutation, Harvard-affiliated Dana-Farber Cancer Institute scientists report in the Oct. 25 issue of the New England Journal of Medicine. In a study involving more than 900 patients with colorectal cancer, the researchers found that, for patients whose tumors harbored a mutation in the gene PI Read more...

Posted
October 24th, 2012

Tagged


No Comments

Flipping the switch that halts obesity

Flipping a newly discovered molecular switch in white fat cells enabled mice to eat a high-calorie diet without becoming obese or developing the inflammation that causes insulin resistance, report Harvard scientists from Dana-Farber Cancer Institute. The researchers say the results, to be published in the Sept. 28 issue of the journal Cell, provide the first known molecular link between thermogenesis (burning calories to produce heat) and the dev Read more...

Posted
September 28th, 2012

Tagged


No Comments

CYCLOPS genes an Achilles’ heel in tumors?

The genomic tumult within tumor cells has provided scientists at the Harvard-affiliated Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT with clues to an entirely new class of genes that may serve as an Achilles’ heel for many forms of cancer. Although most cancer therapy targets genes that cause normal cells to turn cancerous, these new potential drug targets are genes that are essential to all cells, but that have been Read more...

Posted
August 16th, 2012

Tagged


No Comments

New nanoparticles shrink tumors in mice

By sequencing cancer-cell genomes, scientists have discovered vast numbers of genes that are mutated, deleted or copied in cancer cells. This treasure trove is a boon for researchers seeking new drug targets, but it is nearly impossible to test them all in a timely fashion. To help speed up the process, MIT researchers have developed RNA-delivering nanoparticles that allow for rapid screening of new drug targets in mice. In their first mouse s Read more...

Posted
August 16th, 2012

Tagged


No Comments

In obesity battle, beige is the new brown

Scientists at Harvard-affiliated Dana-Farber Cancer Institute have isolated a new type of energy-burning fat cell in adult humans, which they say may have therapeutic potential for treating obesity. Called “beige fat,” the cells are found in scattered pea-sized deposits beneath the skin near the collarbone and along the spine in adult humans. Because this type of fat can burn calories — rather than store them, as “white fat” cells do Read more...

Posted
July 12th, 2012

Tagged


No Comments

When skin cancer cells resist drug treatment

One of cancer’s most frightening characteristics is its ability to return after treatment. In the case of many forms of cancer, including the skin cancer known as melanoma, tailored drugs can eradicate cancer cells in the lab, but often produce only partial, temporary responses in patients. Thus the burning question in the field of cancer research remains: How does cancer evade drug treatment? New research by a team from the Broad Institute of Read more...

Posted
July 5th, 2012

Tagged


No Comments

« Older Entries

Meta

Categories